Clinical Trial

An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment

Study acronym: WILL-EMI NIS
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This non-interventional study (NIS) is designed to collect information on the effectiveness and safety of treatment received in routine clinical care, as well as measure the health-related quality of life (HRQoL) of participants with Type 3 von Willebrand disease (VWD) receiving prophylactic therapy per local standard of care (SOC) over an observation period of at least 24 weeks.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13
notable Enrollment increased: 40 -> 44 participants 2026-06-13
Trial Details
NCT Number NCT06883240
Lead Sponsor Hoffmann-La Roche
Conditions Von Willebrand Disease, Type 3
Enrollment 44 participants
Start Date 2025-04-29
Primary Completion 2026-11-01 (estimated)
Study Completion 2026-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10